Free tool
Drug literature search
Last checked: Nov 20, 2026Source: PubMed, Europe PMC, OpenAlex
314 results in Europe PMC
PubMed plus preprints and full-text open access papers. Showing the first 25. Limited to clinical trials, meta-analyses and systematic reviews.
- Global Epidemiology of Paroxysmal Nocturnal Hemoglobinuria: A Systematic Literature Review.
Zorina O, Beiki O, Holt M, Buisker J, Ferber P, Fermont JM, Kelly RJ. · J Epidemiol Glob Health · 2026 · cited 0 timesOpen accesssystematic review, review-article
- Efficacy and Safety of the C3 Inhibitor Pegcetacoplan in Paroxysmal Nocturnal Hemoglobinuria: A Systematic Review and Meta-Analysis.
Martins KAM, Corcinio MM, Martins BAM, Menegucci G, Faria IC. · Eur J Haematol · 2026 · cited 0 timesmeta-analysis, systematic review
- Indirect treatment comparisons find enhanced effectiveness of pegcetacoplan versus crovalimab in both complement inhibitor-naïve and -experienced patients with paroxysmal nocturnal hemoglobinuria.
Ming Wong RS, Wilson K, Hakimi Z, Parkitny M, Wojciechowski P, Flynn C, Fatoye F. · J Comp Eff Res · 2026 · cited 0 timesOpen accessclinical trial, phase iii, comparative study
- Efficacy and safety of vemircopan as monotherapy in patients with paroxysmal nocturnal hemoglobinuria.
Kulasekararaj A, Browett P, Risitano AM, Patriquin CJ, Yenerel MN, Marceau D, Sahin F, Algarra JL, Ogawa M, Yu J, Cross NB, Notaro R, Lee JW, Brodsky RA. · Blood Adv · 2026 · cited 1 timesOpen accessclinical trial, phase ii
- Improved Iron Overload with Pegcetacoplan in Eculizumab-Experienced Patients with Paroxysmal Nocturnal Hemoglobinuria.
Shammo J, Hillmen P, Blandino P, Abilash V, Kuter DJ. · Int J Mol Sci · 2025 · cited 0 timesOpen accessclinical trial, phase iii, randomized controlled trial
- Efficacy and safety of crovalimab versus eculizumab in complement inhibitor-naïve patients with paroxysmal nocturnal hemoglobinuria: Chinese subgroup analysis of the phase 3 COMMODORE 2 study.
Tong H, Lin Z, Yang C, Wang X, Sun J, Xia L, Shi J, Shi D, Zhang Z, Appius A, He G. · Ann Hematol · 2026 · cited 0 timesOpen accessclinical trial, phase iii, comparative study
- Efficacy and Safety of the C5 Inhibitor Crovalimab in Patients With Paroxysmal Nocturnal Hemoglobinuria: A Systematic Review and Meta-Analysis.
Martins KAM, Corcinio MM, Faria IC, Braga MO, Danielian PLLB, Pittol IP, Américo AD, Scheinberg P. · Eur J Haematol · 2026 · cited 0 timesmeta-analysis, systematic review
- Psychometric performance of the Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue questionnaire among adults with paroxysmal nocturnal hemoglobinuria.
Cella D, Vallow S, Bermann G, McDonald J, Ngerano G, Linton S, Arenson E, Maitra S, Yen G, Galipeau N, Dickie G. · J Patient Rep Outcomes · 2026 · cited 0 timesOpen accessclinical trial, phase iii
- Efficacy and Safety Maintained up to 3 Years in Adults with Paroxysmal Nocturnal Hemoglobinuria Receiving Pegcetacoplan.
de Castro C, Kelly RJ, Griffin M, Patriquin CJ, Mulherin B, Höchsmann B, Selvaratnam V, Wong RSM, Hillmen P, Horneff R, Uchendu UO, Zhang Y, Surova E, Szamosi J, de Latour RP. · Adv Ther · 2025 · cited 3 timesOpen accessclinical trial, phase iii, multicenter study
- Patient-Reported Meaningful Change in Symptoms and Impacts of Paroxysmal Nocturnal Hemoglobinuria (PNH) in Three Phase III Clinical Trials of Iptacopan.
DeCastro C, Sheinberg P, Han B, Vallow S, Bermann G, Dhalke M, Kumar R, Dickie G, Galipeau N, Lamoureux R, Rupinski K, Lowe C, Nieves A, de Fontbrune FS, de Latour RP. · Patient · 2025 · cited 1 timesclinical trial, phase iii
- Safety and efficacy of danicopan in patients with paroxysmal nocturnal hemoglobinuria: a systematic review and meta-analysis.
Muvaffak E, Mokresh ME, Varda A, Lakmoush M, Ilter MK. · Expert Rev Hematol · 2024 · cited 1 timesmeta-analysis, systematic review
- Patient-reported improvements in paroxysmal nocturnal hemoglobinuria treated with iptacopan from 2 phase 3 studies.
Risitano AM, de Castro C, Han B, Kulasekararaj A, Maciejewski JP, Scheinberg P, Ueda Y, Vallow S, Bermann G, Dahlke M, Kumar R, Peffault de Latour R. · Blood Adv · 2025 · cited 9 timesOpen accessclinical trial, phase iii, multicenter study
- Ravulizumab demonstrates long-term efficacy, safety and favorable patient survival in patients with paroxysmal nocturnal hemoglobinuria.
Kulasekararaj A, Brodsky R, Schrezenmeier H, Griffin M, Röth A, Piatek C, Ogawa M, Yu J, Patel AS, Patel Y, Notaro R, Usuki K, Kulagin A, Gualandro S, Füreder W, Peffault de Latour R, Szer J, Lee JW. · Ann Hematol · 2025 · cited 22 timesOpen accessclinical trial, phase iii, multicenter study
- Patient-reported outcomes in patients with paroxysmal nocturnal hemoglobinuria treated with crovalimab and approved C5 inhibitors in the phase III COMMODORE 2 and 1 studies.
Panse J, Han B, Cermak J, Gonzalez Fernandez FA, Gotoh A, Kulasekararaj AG, Kyselova O, Sahin F, Scheinberg P, Schrezenmeier H, Straetmans N, Ueda Y, Chang AC, Gentile B, Stefani J, Uguen M, Röth A. · Ann Hematol · 2025 · cited 1 timesOpen accessclinical trial, phase iii, multicenter study
- Phase II trials of zilucoplan in paroxysmal nocturnal hemoglobinuria.
Kulasekararaj AG, Lehtinen AE, Forsyth C, Gandhi S, Griffin M, Körper S, Mikala G, Muus P, Overgaard U, Patriquin CJ, Pullon H, Shen YM, Spearing R, Szer J, De la Borderie G, Duda PW, Farzaneh-Far R, Ragunathan S, Sayegh CE, Vadysirisack DD, Schrezenmeier H. · Haematologica · 2024 · cited 8 timesletter, clinical trial, phase ii
- Pharmacokinetics, pharmacodynamics, efficacy, and safety of ravulizumab in pediatric paroxysmal nocturnal hemoglobinuria.
Chonat S, Kulagin A, Maschan A, Bartels M, Buechner J, Punzalan R, Richards M, Ogawa M, Hicks E, Yu J, Baruchel A, Kulasekararaj AG. · Blood Adv · 2024 · cited 11 timesOpen accessclinical trial, phase iii, multicenter study
- Normalization of Hemoglobin, Lactate Dehydrogenase, and Fatigue in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Pegcetacoplan.
Mulherin BP, Yeh M, Al-Adhami M, Dingli D. · Drugs R D · 2024 · cited 0 timesOpen accessclinical trial, phase iii, randomized controlled trial
- Hemolysis events in the phase 3 PEGASUS study of pegcetacoplan in patients with paroxysmal nocturnal hemoglobinuria.
Peffault de Latour R, Griffin M, Kelly RJ, Szer J, de Castro C, Horneff R, Tan L, Yeh M, Panse J. · Blood Adv · 2024 · cited 18 timesOpen accessclinical trial, phase iii, research support, non-u.s. gov't
- Comparative clinical efficacy and safety of biosimilar ABP 959 and eculizumab reference product in patients with paroxysmal nocturnal hemoglobinuria.
Kulasekararaj A, Lanza F, Arvanitakis A, Langemeijer S, Chonat S, Tombak A, Hanes V, Cao J, Miller MJ, Colbert A, Shander B, Mytych DT, Chow V, Henary H. · Am J Hematol · 2024 · cited 8 timescomparative study, research support, non-u.s. gov't
- Development of a target concentration intervention to individualize paroxysmal nocturnal hemoglobinuria treatment with pegcetacoplan.
Ter Avest M, Langemeijer SMC, Blijlevens NMA, van de Kar NCAJ, Ter Heine R. · Ann Hematol · 2024 · cited 1 timesOpen accessclinical trial
- Phase 3 randomized COMMODORE 1 trial: Crovalimab versus eculizumab in complement inhibitor-experienced patients with paroxysmal nocturnal hemoglobinuria.
Scheinberg P, Clé DV, Kim JS, Nur E, Yenerel MN, Barcellini W, Bonito D, Giai V, Hus M, Lee Y, Lekue CB, Panse J, Ueda Y, Buatois S, Gentile B, Kiialainen A, Patel H, Sreckovic S, Uguen M, Edwards J, Nagy Z, Kulasekararaj AG. · Am J Hematol · 2024 · cited 46 timesclinical trial, phase iii, comparative study
- Phase 3 randomized COMMODORE 2 trial: Crovalimab versus eculizumab in patients with paroxysmal nocturnal hemoglobinuria naive to complement inhibition.
Röth A, He G, Tong H, Lin Z, Wang X, Chai-Adisaksopha C, Lee JH, Brodsky A, Hantaweepant C, Dumagay TE, Demichelis-Gómez R, Rojnuckarin P, Sun J, Höglund M, Jang JH, Gaya A, Silva F, Obara N, Kelly RJ, Beveridge L, Buatois S, Chebon S, Gentile B, Lundberg P, Sreckovic S, Nishimura JI, Risitano A, Han B. · Am J Hematol · 2024 · cited 47 timesclinical trial, phase iii, comparative study
- Efficacy, Safety, and Quality of Life of Pegcetacoplan in Japanese Patients with Paroxysmal Nocturnal Hemoglobinuria Treated within the Phase 3 PEGASUS Trial.
Nishimori H, Nakazawa H, Tamura S, Uchida T, Usuki K, Szamosi J, de Latour RP, Röth A, Panse J. · Acta Haematol · 2025 · cited 4 timesOpen accessclinical trial, phase iii, multicenter study
- Pegcetacoplan controls hemolysis in complement inhibitor-naive patients with paroxysmal nocturnal hemoglobinuria.
Wong RSM, Navarro-Cabrera JR, Comia NS, Goh YT, Idrobo H, Kongkabpan D, Gómez-Almaguer D, Al-Adhami M, Ajayi T, Alvarenga P, Savage J, Deschatelets P, Francois C, Grossi F, Dumagay T. · Blood Adv · 2023 · cited 59 timesOpen accessclinical trial, phase iii, research support, non-u.s. gov't
- Improvements in hematologic markers and decreases in fatigue with pegcetacoplan for patients with paroxysmal nocturnal hemoglobinuria and mild or moderate anemia (hemoglobin ≥10 g/dL) who had received eculizumab or were naive to complement inhibitors.
Panse J, Daguindau N, Okuyama S, Peffault de Latour R, Schafhausen P, Straetmans N, Al-Adhami M, Persson E, Wong RSM. · PLoS One · 2024 · cited 3 timesOpen accessclinical trial, phase iii, research support, non-u.s. gov't
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.